Aberrant expression of p68 and PDGFR-β have been documented in three major human cancers, including breast cancer 20-23, colon cancer 24, 25, and prostate cancer 26, 27, suggesting the crucial role of both in tumorigenesis and cancer progression. Here, DDX5 is linked to prostate carcinoma.